全球抗感染药物市场 – 行业趋势及 2030 年预测

抗感染药物市场分析及规模

几十年来，抗感染药物一直是多家制药公司的主要业务领域。自过去二十年以来，感染率大幅上升，主要发生在中低收入国家。固定剂量组合等配方方面的一些进步以及对疾病特定治疗的需求不断增加是抗病毒药物需求的主要因素。由于目标疾病发病率的增加和对抗感染药物的宣传力度不断加大，预计抗感染药物市场将大幅增长。

Data Bridge Market Research 分析了 2023-2030 年预测期内抗感染药物市场的增长率。在上述预测期内，抗感染药物市场的预期复合年增长率趋于 4% 左右。2022 年市场价值为 1350 亿美元，到 2030 年将增长至 1847 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

抗感染药物市场范围和细分

Market Definition

Anti-infective drugs belongs to a class of therapeutics which causes suppression of muscle spasms. These type of drugs help in the stimulation of smooth muscle relaxation especially in the gastrointestinal tract. Antispasmodic medications generally treat symptoms such as stomach pain and cramping. They are most commonly used for the treatment of irritable bowel syndrome symptoms.  

Global Anti-Infective Drugs Market Dynamics

Drivers

• Increasing Awareness About Infectious Diseases

There has been major growth in the number of multidrug-resistant organisms across numerous parts of the world, that further surges the importance of innovation in the anti-infective agents. Numerous institutes have established specific initiatives or campaigns to increase the awareness about infectious diseases among the public. For instance, the World Health Organization performed the World Antimicrobial Awareness Week (WAAW) with the theme, ‘Spread Awareness, Stop Resistance’ in November 2021 to raise awareness about antimicrobial resistance. Thus, this awareness initiatives boost the market growth.

• Growing Demand for Oral Drugs

Oral drugs is estimated to increase the market growth. The segment is expected to rise the global market as many of the products are available in capsule form and tablet form and it is a very common and convenient route of administration.

Opportunities

• Launch of Anti-infective Drugs

Major market players are releasing many products that are helping in boosting the growth of the market.  For instance, in February 2021, Pfizer announced the launch of the C. difficile Awareness Initiative. C. difficile is an infectious bacterium that can cause a serious and potentially life-threatening infection related with symptoms from diarrhea to severe intestinal inflammation. The article specified that an estimate of about 462,000 C. difficile infection cases were being registered in the U.S. each year. The growing number of initiatives by several organizations and major market players on spreading awareness regarding infectious diseases are projected to boost the market growth. Furthermore, Xellia Pharmaceuticals, which is a pharmaceutical manufacturer specializing in anti-infective treatments, in August 2021, opened its manufacturing site in Cleveland, Ohio in U.S. The company released the first anti-infectives which is manufactured at the site for distribution to U.S. hospitals. Such activities are projected to increase the market growth during the forecast period.

Restraints/Challenges

• Lack of skilled professionals

The huge lack of qualified personnel who are not aware of the drugs options to give patients to could hamper the growth of the global anti-infective drugs market during the forecast period 2023-2030.

• Side-effects of anti-infective drugs

Several side effects such as weakness, dizziness, blurred vision, rashes, nausea, dry mouth, and abdominal bloating hamper the market growth. Any of the drug use is restricted because of the government developed guidelines to monitor how and where the medications are utilized.

This anti-infective drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anti-infective drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Anti-Infective Drugs Market Scope

The anti-infective drugs market is segmented on the basis of product type, indication,  route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Antibiotics
• Antivirals
• Antifungals
• Others

Indication

• HIV Infections
• Pneumonia
• Hepatitis
• Herpes Simplex Virus
• Influenza
• Others

Route of Administration

• Oral
• Topical
• Parenteral
• Others

End User

• 医院
• 家庭护理
• 专科诊所
• 其他的

分销渠道

• 医院药房
• 网上药店
• 零售药店

抗感染药物市场区域分析/见解

对抗感染药物市场进行了分析，并根据上述产品类型、适应症、给药途径、分销渠道和最终用户提供了市场规模洞察和趋势。

抗感染药物市场报告涉及的主要国家 有：北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于医疗保健基础设施完善、社会意识不断增强、分销渠道完善以及美国和加拿大电子商务的蓬勃发展，北美在预测期内抗感染药物市场一直呈现积极增长态势。

亚太地区占据市场主导地位，因为主要市场参与者越来越关注建立众多具有显著增长的新兴经济体。随着该地区多家新医院和药店的开业，市场正在扩大。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球抗感染药物市场份额分析

抗感染药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对抗感染药物市场的关注有关

抗感染药物市场的主要参与者包括：

• 武田药品工业株式会社 (日本)
• 强生服务公司 (美国)
• 勃林格殷格翰国际有限公司 (德国)
• Abbvie, Inc（美国）
• 太阳制药工业有限公司 (印度)
• 赛诺菲（法国）
• 葛兰素史克公司（英国）
• 诺华公司（瑞士）
• 辉瑞公司（美国）
• Amneal Pharmaceuticals LLC.（美国）
• Alvogen（美国）
• Hikma Pharmaceuticals PLC（英国）
• Alembic Pharmaceuticals Limited（印度）
• Zydus 集团 (印度)

SKU-52944